Inventiva Moves Up In NASH, Hitting Multiple Phase IIb Endpoints

 
• By Joseph Haas

A month after Genfit’s Phase III failure, Inventiva hits multiple endpoints in a Phase IIb study of pan-PPAR agonist lanifibranor – likely drawing partnering or acquisition interest. Ascletis offers Phase II evidence for its NASH drug.

Excited multiracial colleagues celebrating team victory giving high five in office, happy employees group join hands together promising loyalty engagement, expressing trust unity support in teamwork
Inventiva may have moved toward the front of the pack in NASH with new data

More from Clinical Trials

More from R&D